Matches in Wikidata for { <http://www.wikidata.org/entity/Q37646432> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- Q37646432 description "article científic" @default.
- Q37646432 description "article scientifique" @default.
- Q37646432 description "articolo scientifico" @default.
- Q37646432 description "artigo científico" @default.
- Q37646432 description "artículu científicu espublizáu en 2009" @default.
- Q37646432 description "bilimsel makale" @default.
- Q37646432 description "scientific article published on 05 December 2009" @default.
- Q37646432 description "vedecký článok" @default.
- Q37646432 description "vetenskaplig artikel" @default.
- Q37646432 description "videnskabelig artikel" @default.
- Q37646432 description "vědecký článek" @default.
- Q37646432 description "wetenschappelijk artikel" @default.
- Q37646432 description "wissenschaftlicher Artikel" @default.
- Q37646432 description "наукова стаття, опублікована в грудні 2009" @default.
- Q37646432 description "научни чланак" @default.
- Q37646432 description "գիտական հոդված հրատարակված 2009 թվականի դեկտեմբերի 5-ին" @default.
- Q37646432 description "مقالة علمية نشرت في 05 ديسمبر 2009" @default.
- Q37646432 name "Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis." @default.
- Q37646432 name "Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis." @default.
- Q37646432 name "Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis." @default.
- Q37646432 type Item @default.
- Q37646432 label "Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis." @default.
- Q37646432 label "Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis." @default.
- Q37646432 label "Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis." @default.
- Q37646432 prefLabel "Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis." @default.
- Q37646432 prefLabel "Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis." @default.
- Q37646432 prefLabel "Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis." @default.
- Q37646432 P1433 Q37646432-D9662723-F32B-4E74-89C8-CF33AF26DF9E @default.
- Q37646432 P1476 Q37646432-F133FA15-9008-474A-906C-261442C11BC4 @default.
- Q37646432 P2093 Q37646432-304F21A8-2962-4D41-938C-83CED679B97E @default.
- Q37646432 P2093 Q37646432-6487BAB2-498D-4C29-AB78-7FEA11AADAA1 @default.
- Q37646432 P2093 Q37646432-A99C7981-B371-4C80-8D04-1CBC5F749D43 @default.
- Q37646432 P2093 Q37646432-AD6ED6B1-CDBC-4618-B700-2F7D1BE601D1 @default.
- Q37646432 P2093 Q37646432-F218FE5F-EE12-460E-97FC-05A99BCC7973 @default.
- Q37646432 P2888 Q37646432-9544927F-7244-47AE-9AA7-A547EC414C98 @default.
- Q37646432 P304 Q37646432-AA7587AB-A4AB-4A5E-AEA9-35BE58DC9B2D @default.
- Q37646432 P31 Q37646432-4f051f8a-5e2b-4743-bb73-0cf0913b1f23 @default.
- Q37646432 P31 Q37646432-97C8FCE9-2980-45DB-AC95-6555DF75D165 @default.
- Q37646432 P31 Q37646432-fcdbb4b5-1827-4b2d-b9f9-8779d03048e6 @default.
- Q37646432 P356 Q37646432-54F7C733-D293-40B5-A6D9-96D466461EC2 @default.
- Q37646432 P433 Q37646432-51556A59-2450-4636-BA2C-6B5E337EA98A @default.
- Q37646432 P478 Q37646432-6A686F65-96D4-47C7-A86E-DF87CF4B61DF @default.
- Q37646432 P50 Q37646432-14467C87-66AE-4C29-B780-8DCF85D880D3 @default.
- Q37646432 P577 Q37646432-C3B626DD-78AB-4EAE-9624-0EE6BF917DF5 @default.
- Q37646432 P698 Q37646432-EDE8C69D-F9D4-4160-AFA4-4B50A71BE37F @default.
- Q37646432 P921 Q37646432-0DCE0059-7032-49D4-8EBE-EBC6E5C6DFF9 @default.
- Q37646432 P921 Q37646432-64072461-EAA8-4F2F-9E13-8B3F9C51A9C4 @default.
- Q37646432 P921 Q37646432-C91836A2-9EA8-40B2-911E-882A40C94EA4 @default.
- Q37646432 P921 Q37646432-F68EB6FF-F458-4C62-BA1F-A603B9A84FEE @default.
- Q37646432 P356 S00280-009-1170-Y @default.
- Q37646432 P698 19967539 @default.
- Q37646432 P1433 Q326137 @default.
- Q37646432 P1476 "Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis" @default.
- Q37646432 P2093 "Bill Poland" @default.
- Q37646432 P2093 "Brett E Houk" @default.
- Q37646432 P2093 "Carlo L Bello" @default.
- Q37646432 P2093 "George D Demetri" @default.
- Q37646432 P2093 "Lee S Rosen" @default.
- Q37646432 P2888 s00280-009-1170-y @default.
- Q37646432 P304 "357-371" @default.
- Q37646432 P31 Q13442814 @default.
- Q37646432 P31 Q7318358 @default.
- Q37646432 P31 Q815382 @default.
- Q37646432 P356 "10.1007/S00280-009-1170-Y" @default.
- Q37646432 P433 "2" @default.
- Q37646432 P478 "66" @default.
- Q37646432 P50 Q42721742 @default.
- Q37646432 P577 "2009-12-05T00:00:00Z" @default.
- Q37646432 P698 "19967539" @default.
- Q37646432 P921 Q181600 @default.
- Q37646432 P921 Q323936 @default.
- Q37646432 P921 Q725307 @default.
- Q37646432 P921 Q815382 @default.